Francesco Silvestris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5055242/publications.pdf

Version: 2024-02-01

175 papers 6,273 citations

76326 40 h-index 70 g-index

178 all docs

178 docs citations

178 times ranked

10114 citing authors

#	Article	IF	CITATIONS
1	Obesity as a Major Risk Factor for Cancer. Journal of Obesity, 2013, 2013, 1-11.	2.7	669
2	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879463.	3.2	317
3	Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis, 2005, 26, 883-891.	2.8	230
4	Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukinâ€18. Arthritis and Rheumatism, 2008, 58, 251-262.	6.7	207
5	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 2017, 8, 106132-106142.	1.8	174
6	Erdheim–Chester disease: A systematic review. Critical Reviews in Oncology/Hematology, 2015, 95, 1-11.	4.4	153
7	Metastatic bone disease: Pathogenesis and therapeutic options. Journal of Bone Oncology, 2019, 15, 100205.	2.4	153
8	Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood, 2002, 99, 1305-1313.	1.4	97
9	Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clinical and Experimental Immunology, 2008, 154, 247-254.	2.6	97
10	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget, 2018, 9, 20826-20837.	1.8	97
11	Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. Aids, 1996, 10, 131-141.	2.2	94
12	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. British Journal of Haematology, 2004, 126, 475-486.	2.5	90
13	In vitro differentiation of human oocyte-like cells from oogonial stem cells: single-cell isolation and molecular characterization. Human Reproduction, 2018, 33, 464-473.	0.9	90
14	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Frontiers in Oncology, 2019, 9, 1148.	2.8	90
15	The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology, 2019, 109, 83-99.	2.5	87
16	Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. Oncologist, 2016, 21, 404-417.	3.7	83
17	Autoreactivity in HIV-1 Infection: The Role of Molecular Mimicry. Clinical Immunology and Immunopathology, 1995, 75, 197-205.	2.0	81
18	Studies of anti-f(ab')2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus. Arthritis and Rheumatism, 1984, 27, 1387-1396.	6.7	80

#	Article	IF	Citations
19	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. Oncolmmunology, 2018, 7, e1387706.	4.6	76
20	Antibody Production and In Vitro Behavior of CD27-Defined B-Cell Subsets: Persistent Hepatitis C Virus Infection Changes the Rules. Journal of Virology, 2006, 80, 3923-3934.	3.4	69
21	Th1 cytokines in the pathogenesis of lupus nephritis: The role of IL-18. Autoimmunity Reviews, 2005, 4, 542-548.	5.8	66
22	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. British Journal of Haematology, 2003, 122, 39-52.	2.5	65
23	Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	4.0	62
24	Desmoid Tumors in Familial Adenomatous Polyposis. Anticancer Research, 2017, 37, 3357-3366.	1.1	62
25	Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clinical and Experimental Immunology, 2006, 146, 21-31.	2.6	59
26	The immune escape in melanoma: role of the impaired dendritic cell function. Expert Review of Clinical Immunology, 2014, 10, 1395-1404.	3.0	56
27	Immuneâ€'related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). Oncology Letters, 2017, 14, 5671-5680.	1.8	54
28	PTHrP Produced by Myeloma Plasma Cells Regulates Their Survival and Pro-Osteoclast Activity For Bone Disease Progression. Journal of Bone and Mineral Research, 2014, 29, 55-66.	2.8	53
29	Para- and perirenal ultrasonographic fat thickness is associated with 24-hours mean diastolic blood pressure levels in overweight and obese subjects. BMC Cardiovascular Disorders, 2015, 15, 108.	1.7	52
30	Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Annals of Hematology, 1995, 70, 313-318.	1.8	51
31	Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood, 2001, 97, 1155-1164.	1.4	51
32	Cytokine Overproduction, T-Cell Activation, and Defective T-Regulatory Functions Promote Nephritis in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	51
33	CD8+ /CD57+ cells and apoptosis suppress T-cell functions in multiple myeloma. British Journal of Haematology, 1998, 100, 469-477.	2.5	49
34	The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. International Journal of Clinical and Laboratory Research, 1998, 28, 127-134.	1.0	48
35	Mesenchymal Stem Cells: A New Promise in Anticancer Therapy. Stem Cells and Development, 2011, 20, 1-10.	2.1	47
36	New Insights Into the Molecular Pathogenesis of Langerhans Cell Histiocytosis. Oncologist, 2014, 19, 151-163.	3.7	47

#	Article	IF	Citations
37	<i>In vitro</i> antiâ€myeloma activity of <scp>TRAIL</scp> â€expressing adiposeâ€derived mesenchymal stem cells. British Journal of Haematology, 2012, 157, 586-598.	2.5	46
38	Myeloma bone disease: Pathogenetic mechanisms and clinical assessment. Leukemia Research, 2007, 31, 129-138.	0.8	44
39	The Interplay of Chemokines and Dendritic Cells in the Pathogenesis of Lupus Nephritis. Annals of the New York Academy of Sciences, 2005, 1051, 421-432.	3.8	43
40	Immature dendritic cells in multiple myeloma are prone to osteoclastâ€like differentiation through interleukinâ€17 <scp>A</scp> stimulation. British Journal of Haematology, 2013, 161, 821-831.	2.5	42
41	Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. Journal of Hypertension, 2006, 24, 1307-1318.	0.5	41
42	Umbilical Cord Mesenchymal Stem Cells: Role of Regulatory Genes in Their Differentiation to Osteoblasts. Stem Cells and Development, 2009, 18, 1211-1220.	2.1	41
43	Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis. Journal of Translational Medicine, 2019, 17, 230.	4.4	41
44	Does cilengitide deserve another chance?. Lancet Oncology, The, 2014, 15, e584-e585.	10.7	40
45	miRNAs in melanoma: a defined role in tumor progression and metastasis. Expert Review of Clinical Immunology, 2016, 12, 79-89.	3.0	40
46	Functional osteoclast-like transformation of cultured human myeloma cell lines. British Journal of Haematology, 2005, 130, 926-938.	2.5	39
47	Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?. Oncologist, 2011, 16, 1040-1048.	3.7	38
48	Bone metastases in hepatocellular carcinoma: an emerging issue. Cancer and Metastasis Reviews, 2014, 33, 333-342.	5.9	38
49	${\rm Av}\hat{\rm I}^2$ 3 integrin: Pathogenetic role in osteotropic tumors. Critical Reviews in Oncology/Hematology, 2015, 96, 183-193.	4.4	38
50	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. International Journal of Molecular Sciences, 2020, 21, 52.	4.1	38
51	Targeted Therapies in Cancer. BioDrugs, 2010, 24, 77-88.	4.6	36
52	Obesity and Heart Failure. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2013, 13, 51-57.	1.2	36
53	Discrepancy in the expression of autoantibodies in healthy aged individuals. Clinical Immunology and Immunopathology, 1985, 35, 234-244.	2.0	35
54	Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?. Frontiers in Oncology, 2019, 9, 521.	2.8	35

#	Article	IF	Citations
55	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget, 2018, 9, 25355-25382.	1.8	34
56	25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 838-844.	1,2	34
57	Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation inÂvitro. Experimental Hematology, 2011, 39, 773-783.e1.	0.4	33
58	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	2.5	33
59	Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells. Clinical Cancer Research, 2008, 14, 6081-6091.	7.0	32
60	\hat{l}^23 Integrin Subunit Mediates the Bone-Resorbing Function Exerted by Cultured Myeloma Plasma Cells. Cancer Research, 2009, 69, 6738-6746.	0.9	32
61	Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. Lupus, 2003, 12, 8-14.	1.6	31
62	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. Cancer Treatment Reviews, 2018, 69, 21-28.	7.7	31
63	Oversecretion of Cytokines and Chemokines in Lupus Nephritis Is Regulated by Intraparenchymal Dendritic Cells. Annals of the New York Academy of Sciences, 2009, 1173, 449-457.	3.8	29
64	Mediterranean Diet and cancer risk: an open issue. International Journal of Food Sciences and Nutrition, 2016, 67, 593-605.	2.8	29
65	The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. Tumor Biology, 2019, 41, 101042831983713.	1.8	29
66	Next-generation Sequencing (NGS) Analysis on Single Circulating Tumor Cells (CTCs) with No Need of Whole-genome Amplification (WGA). Cancer Genomics and Proteomics, 2017, 14, 173-179.	2.0	29
67	Possible Role of Hyperinsulinemia and Insulin Resistance in Lower Vitamin D Levels in Overweight and Obese Patients. BioMed Research International, 2013, 2013, 1-6.	1.9	28
68	Relationship of para- and perirenal fat and epicardial fat with metabolic parameters in overweight and obese subjects. Eating and Weight Disorders, 2019, 24, 67-72.	2.5	28
69	Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide. Leukemia Research, 2010, 34, 243-249.	0.8	27
70	Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1–infected Patients. Journal of Experimental Medicine, 1996, 184, 2287-2300.	8.5	26
71	Increased IL-18 Production by Dendritic Cells in Active Inflammatory Myopathies. Annals of the New York Academy of Sciences, 2007, 1107, 184-192.	3.8	26
72	Boneâ€Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?. Oncologist, 2009, 14, 264-275.	3.7	26

#	Article	IF	CITATIONS
73	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Scientific Reports, 2019, 9, 18614.	3.3	26
74	Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clinical and Experimental Immunology, 1998, 114, 179-188.	2.6	25
75	Therapeutic approaches to myeloma bone disease: An evolving story. Cancer Treatment Reviews, 2012, 38, 787-797.	7.7	25
76	Targeting bone metastatic cancer: Role of the mTOR pathway. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 248-254.	7.4	25
77	Ovarian cancer: Novel molecular aspects for clinical assessment. Critical Reviews in Oncology/Hematology, 2017, 117, 12-29.	4.4	25
78	pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo. Stem Cell Research and Therapy, 2017, 8, 206.	5.5	25
79	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. British Journal of Cancer, 2019, 120, 294-300.	6.4	25
80	Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leukemia Research, 2008, 32, 611-623.	0.8	23
81	NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget, 2016, 7, 57414-57429.	1.8	23
82	Susceptibility to ischaemic heart disease: Focusing on genetic variants for ATP-sensitive potassium channel beyond traditional risk factors. European Journal of Preventive Cardiology, 2021, 28, 1495-1500.	1.8	22
83	Low 25 Hydroxyvitamin D Levels are Independently Associated with Autoimmune Thyroiditis in a Cohort of Apparently Healthy Overweight and Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2018, 18, 646-652.	1.2	22
84	Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma. International Journal of Hematology, 2003, 78, 121-125.	1.6	21
85	Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cellular Signalling, 2013, 25, 1108-1117.	3.6	21
86	A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression. Stem Cells and Development, 2015, 24, 1457-1470.	2.1	21
87	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987554.	3.2	21
88	Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT <i>in vitro</i> . Oncotarget, 2017, 8, 22534-22549.	1.8	21
89	A Lipidomic Approach to Identify Potential Biomarkers in Exosomes From Melanoma Cells With Different Metastatic Potential. Frontiers in Physiology, 2021, 12, 748895.	2.8	21
90	Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. BMC Cancer, 2016, 16, 87.	2.6	20

#	Article	IF	CITATIONS
91	Immune Profile of Obese People and In Vitro Effects of Red Grape Polyphenols on Peripheral Blood Mononuclear Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	4.0	20
92	Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. Neuroendocrinology, 2016, 103, 321-334.	2.5	19
93	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. Leukemia and Lymphoma. 2017, 58, 2633-2641.	1.3	19
94	Role of Active Drug Transporters in Refractory Multiple Myeloma. Current Topics in Medicinal Chemistry, 2009, 9, 218-224.	2.1	18
95	Uric Acid, Metabolic Syndrome and Atherosclerosis: The Chicken or the Egg, Which Comes First?. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2018, 18, 251-259.	1.2	18
96	In vitro inhibition of anti-DNA producing cells from systemic lupus erythematosus patients by autologous anti-F(abâ \in 2)2 antibodies. Clinical Immunology and Immunopathology, 1987, 42, 50-62.	2.0	17
97	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opinion on Biological Therapy, 2014, 14, 15-26.	3.1	17
98	Large Extracellular Vesicles—A New Frontier of Liquid Biopsy in Oncology. International Journal of Molecular Sciences, 2020, 21, 6543.	4.1	17
99	Osteoclast-like Cell Formation by Circulating Myeloma B Lymphocytes: Role of RANK-L. Leukemia and Lymphoma, 2004, 45, 377-380.	1.3	16
100	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer, 2015, 15, 692.	2.6	16
101	Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. Scientific Reports, 2019, 9, 17276.	3.3	16
102	Uterine carcinosarcoma: An overview. Critical Reviews in Oncology/Hematology, 2021, 163, 103369.	4.4	16
103	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica, 2016, 101, e196-e199.	3.5	15
104	Cell Fusion and Hyperactive Osteoclastogenesis in Multiple Myeloma. Advances in Experimental Medicine and Biology, 2011, 714, 113-128.	1.6	15
105	Arterial hypertension in obesity: relationships with hormone and anthropometric parameters. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 240-247.	2.8	14
106	Lenalidomide in multiple myeloma: current experimental and clinical data. European Journal of Haematology, 2012, 88, 279-291.	2.2	14
107	Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family. International Journal of Molecular Sciences, 2018, 19, 285.	4.1	14
108	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. Cardiovascular Drugs and Therapy, 2021, 35, 505-519.	2.6	14

#	Article	IF	Citations
109	An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. Experimental Hematology, 2014, 42, 897-908.e1.	0.4	13
110	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. Neuroendocrinology, 2021, 111, 207-216.	2.5	13
111	Cross-reactivity of human igg anti-F(ab′)2 antibody with DNA and other nuclear antigens. Arthritis and Rheumatism, 1997, 40, 109-123.	6.7	12
112	Independent Relationship of Osteocalcin Circulating Levels with Obesity, Type 2 Diabetes, Hypertension, and HDL Cholesterol. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 16, 270-275.	1.2	12
113	New clinical and immunological trends in cryoglobulinemia. Research in Clinic and Laboratory, 1980, 10, 51-57.	0.3	11
114	Affinity columns containing anti-DNA ld+ human myeloma proteins adsorb human epibodies from intravenous gamma globulin. Arthritis and Rheumatism, 1997, 40, 683-693.	6.7	11
115	Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. International Journal of Clinical and Laboratory Research, 1998, 28, 215-225.	1.0	11
116	In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1921-1931.	1.3	11
117	Relationship between C3 Levels and Common Carotid Intima-Media Thickness in Overweight and Obese Patients. Obesity Facts, 2011, 4, 159-163.	3.4	11
118	Novel lenalidomide-based combinations for treatment of multiple myeloma. Critical Reviews in Oncology/Hematology, 2013, 85, 9-20.	4.4	11
119	1,25(OH)2 vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells. Experimental Cell Research, 2017, 358, 260-268.	2.6	11
120	Pulmonary enteric adenocarcinoma: an overview. Expert Reviews in Molecular Medicine, 2020, 22, e1.	3.9	11
121	Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infection. Clinical Immunology and Immunopathology, 1989, 53, 329-340.	2.0	10
122	Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis. Leukemia and Lymphoma, 2002, 43, 1527-1533.	1.3	10
123	Abdominal Obesity Is Characterized by Higher Pulse Pressure: Possible Role of Free Triiodothyronine. Journal of Obesity, 2012, 2012, 1-5.	2.7	10
124	Cilengitide restrains the osteoclastâ€like bone resorbing activity of myeloma plasma cells. British Journal of Haematology, 2016, 173, 59-69.	2.5	10
125	Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report. Frontiers in Oncology, 2019, 9, 139.	2.8	10
126	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. Frontiers in Oncology, 2020, 10, 1652.	2.8	10

#	Article	IF	CITATIONS
127	Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090541.	3.2	10
128	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 2022, 126, 419-429.	6.4	10
129	Local treatment for focal progression in metastatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 405-409.	3.1	10
130	Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and $\hat{l}\pm$ -interferon therapy. International Journal of Clinical and Laboratory Research, 1995, 25, 79-83.	1.0	9
131	Functional expression of the calcitonin receptor by human T and B cells. Human Immunology, 2009, 70, 678-685.	2.4	9
132	Shared V-Region Antigens and Cross-Reacting Specificities of Human IgG Anti-F(ab′)2and Anti-DNA Antibodies. Clinical Immunology and Immunopathology, 1996, 80, 194-203.	2.0	8
133	VEINCTR-N, an Immunogenic Epitope of Fas (CD95/Apo-I), and Soluble Fas Enhance T-cell Apoptosis in vitro. II. Functional Analysis and Possible Implications in HIV-1 Disease. Molecular Medicine, 2000, 6, 509-526.	4.4	8
134	<i>ALK</i> gene alterations in cancer: biological aspects and therapeutic implications. Pharmacogenomics, 2017, 18, 277-292.	1.3	8
135	Cutaneous metastasis as a primary presentation of a pulmonary enteric adenocarcinoma. International Journal of Biological Markers, 2019, 34, 421-426.	1.8	8
136	First prospective data on breast cancer patients from the multicentre italian bone metastasis database. Scientific Reports, 2021, 11, 4329.	3.3	8
137	Molecular Specificities of CD4+ T Cell-Reactive IgM in Human Immunodeficiency Virus (HIV-1) Infection. Clinical Immunology and Immunopathology, 1994, 70, 40-46.	2.0	7
138	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 72.	3.0	7
139	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 581130.	2.8	7
140	Independent Relationship between Serum Osteocalcin and Uric Acid in a Cohort of Apparently Healthy Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 17, 207-212.	1.2	7
141	Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy. Current Pharmaceutical Design, 2011, 17, 1979-1983.	1.9	6
142	Application of "omics―sciences to the prediction of bone metastases from breast cancer: State of the art. Journal of Bone Oncology, 2021, 26, 100337.	2.4	6
143	Distribution of anti-F(abâ \in 2)2 antibodies and the 16/6 idiotype in systemic lupus erythematosus (SLE) probands and kindreds. Journal of Clinical Immunology, 1989, 9, 462-468.	3.8	5
144	Nef protein induces differential effects in CD8+cells from HIV-1-infected patients. European Journal of Clinical Investigation, 1999, 29, 980-991.	3.4	5

#	Article	IF	CITATIONS
145	LFA-1 expression on CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFN \hat{l}^2 -1a. Journal of the Neurological Sciences, 2001, 186, 65-73.	0.6	5
146	Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. Journal of Clinical Oncology, 2015, 33, e66-e70.	1.6	5
147	Parallelism of serum anti-F(abâ \in 2)2 and anti-cationic IgG reactivities in patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1991, 59, 256-270.	2.0	4
148	Monoclonal antibodies against human anti-F($ab\hat{a}\in^2$)2 antibodies react with light chain epitopes. Clinical Immunology and Immunopathology, 1991, 59, 139-155.	2.0	4
149	Distribution and Antigenic Analysis of Circulating F(ab′)2-Reactive IgG in Patients with HIV-1 Infection. Clinical Immunology and Immunopathology, 1994, 73, 229-234.	2.0	4
150	Urinary loss of immunoglobulin G anti-F(ab′)2 and anti-DNA antibody in systemic lupus erythematosus nephritis. Translational Research, 1998, 132, 210-222.	2.3	4
151	Immunogenicity of an Eight Amino Acid Domain Shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and Antigenic Analysis. Molecular Medicine, 2000, 6, 494-508.	4.4	4
152	Anti-Fas (CD95/Apo-I) Autoantibodies and Soluble Fas Levels Concur in T Cell Depletion in HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2001, 17, 603-614.	1.1	4
153	Cytotherapies in multiple myeloma: a complementary approach to current treatments?. Expert Opinion on Biological Therapy, 2013, 13, S23-S34.	3.1	4
154	Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2014, 13, 301-305.	1.2	4
155	Expression of F4, 8.12, 3I, and 16/6 Anti-DNA Idiotype-Related Antigens on Cationic Human IgG Myeloma Proteins. Clinical Immunology and Immunopathology, 1994, 73, 215-223.	2.0	3
156	Molecular localization of human IgG anti-F(abâ \in 2)2 reactivity with variable- and constant-region \hat{l} » light-chain epitopes. Journal of Clinical Immunology, 1995, 15, 349-362.	3.8	3
157	Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma. Experimental Hematology, 2017, 47, 48-53.	0.4	3
158	Characterization of a Rare Nonpathogenic Sequence Variant (c.1905C>T) of the Dihydropyrimidine Dehydrogenase Gene (DPYD). International Journal of Biological Markers, 2017, 32, 357-360.	1.8	3
159	Human anti-F(ab′)2 antibodies show preferential reactivity for F(ab′)2 molecules bearing λ light chains. Clinical Immunology and Immunopathology, 1992, 65, 176-182.	2.0	2
160	Differential isotype expression and binding properties of T cell-reactive antibodies in human immunodeficiency virus (HIV) infection. Journal of Clinical Immunology, 1992, 12, 107-115.	3.8	2
161	Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma. Journal of Translational Medicine, $2015,13,.$	4.4	2
162	Characterization of a Rare Nonpathogenic Methylenetetrahydrofolatereductase (MTHFR) Gene Mutation p.Lys215del in a Southern Italian family. Human Mutation, 2017, 38, 120-121.	2.5	2

#	Article	IF	CITATIONS
163	Animal-type melanoma: dog or wolf? A review of the literature and a case report. Expert Reviews in Molecular Medicine, 2018, 20, e5.	3.9	2
164	DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers. International Journal of Molecular Sciences, 2020, 21, 6096.	4.1	2
165	TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing. Leukemia and Lymphoma, 2021, 62, 337-347.	1.3	2
166	Cell Fusion in Myeloma Marrow Microenvironment: Role in Tumor Progression. Critical Reviews in Oncogenesis, 2013, 18, 75-95.	0.4	2
167	The management of refractory carcinoid syndrome: challenges and opportunities ahead. Journal of Medical Economics, 2018, 21, 241-243.	2.1	1
168	Gene Fusion in NSCLC., 2019,, 443-464.		1
169	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. Blood, 2013, 122, 4383-4383.	1.4	1
170	Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL). Blood, 2012, 120, 1645-1645.	1.4	1
171	Upregulation of erythroblast apoptosis by malignant plasma cells: a new pathogenetic mechanism of anemia in multiple myeloma. Reviews in Clinical and Experimental Hematology, 2002, Suppl 1, 39-46.	0.1	1
172	IgG Anti-F(ab′)2 Antibodies from SLE Patients React with Immunodominant Residues in κ CDRs, but Show Reduced Cκ Region Reactivity. Clinical Immunology and Immunopathology, 1995, 77, 366-373.	2.0	0
173	Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker. Journal of Translational Medicine, 2015, 13, .	4.4	0
174	Management of NETs in the Precision Medicine Era. , 2019, , 575-589.		0
175	Targeted Therapies for Bone Metastases. Current Clinical Pathology, 2015, , 249-266.	0.0	O